Pricing Log in Create free account
Friday 6 November 2026 Export BIO’s income statement to Excel — free account

Bio-Rad Laboratories, Inc.

BIO Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue
+0.52%
EPS
+234.8%
Free cash flow
+8.07%
Total debt
+0.11%

Quarter to September 2026, against a year earlier

382.51 13.51 +3.66%
Market cap
$9.9B
P/E
10.0×
Fwd P/E
44.7×
Dividend yield
—
F-score
5/9
Altman Z
3.20
Beneish M
−2.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Bio-Rad Laboratories, Inc. 10-K filed Feb 13, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 9:50 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 14, 2025: 3 added · 4 removed · 15 modified; 5 with only figures updated

  1. Modified · General

    Bio-Rad Laboratories, Inc. (referred to in this report as “Bio-Rad,” “we,” “us,” “the Company,” and “our”) is a multinational developer, manufacturer, and worldwide distributor of our own life science research and clinical diagnostics products. Bio-Radcompany that develops, manufactures, and supplies life science research, healthcare, analytical chemistry and other markets with a broad rangeportfolio of products and instruments, systems used to separate complex chemical and biological materials and to identify, reagents, analyze and purify their componentsconsumables.